Pharmaron

San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Find alternatives to Pharmaron for AAV →
Claimed Profile AAV Lentiviral Plasmid mAb Antibody Recombinant Protein Biosimilars
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
86.9
Signal Score
✓ FDA Inspections (5) ○ Clinical Trials ○ SEC Filings ✓ Press (3) ○ EMA GMP ✓ MHRA GMP (1) ✓ HC GMP (3)

Quick Facts: Pharmaron

Signal Score
86.9/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Bonus: 4 consecutive NAI inspections
Headquarters
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Modalities
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Pharmaron

Chinese CRO/CDMO with US CGT operations.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Bonus: 4 consecutive NAI inspections
Sources: FDA Data Dashboard, MHRA GMDP
Bonus: 4 consecutive NAI inspections
FDA Inspections5 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-08-14)
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2025-03-24
HC Attribution3 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 4 consecutive NAI inspections
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 68.0
2 manufacturing sites
Broad modality coverage (7 modalities)
Sites: San Diego, CA, Shaoxing, China, Liverpool, UK, Ningbo China
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
StatusAvailable
2 manufacturing sites
Broad modality coverage (7 modalities)
Sites: San Diego, CA, Shaoxing, China, Liverpool, UK, Ningbo China
Press Signals3 articles (not scored)
2 manufacturing sites
Broad modality coverage (7 modalities)

Pharmaron FDA Inspection History

2026-08
2025-07
2025-01
2024-09
2022-02
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-08-14
Pharmaron (Ningbo) Technology Development Co., Ltd.
Ningbo Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2025-07-17
Pharmaron Manufacturing Services (US) LLC
Coventry, Rhode Island Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2025-01-17
Pharmaron (Exton) Lab Services LLC
Exton, Pennsylvania Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2024-09-27
Pharmaron (Exton) Lab Services LLC
Exton, Pennsylvania Facility-linked
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2022-02-24
Pharmaron Manufacturing Services (UK) Ltd.
Cramlington Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Pharmaron MHRA GMP Compliance 1 certificates

2025-03
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK API 22857 Insp GMP 22857/36790-0009 PHARMARON MANUFACTURING SERVICES (UK) LTD CRAMLINGTON NE23 3JL 2025-03-24 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 3 articles

Company announcements, not verified evidence. They do not change any score.
financial 2026-10-28
Pharmaron Achieves Record-High Revenue in First Three Quarters; New CDMO Orders Grow Over 40% | Financial Report Analysis - 富途牛牛
Pharmaron Achieves Record-High Revenue in First Three Quarters; New CDMO Orders Grow Over 40% | Financial Report Analysis  富途牛牛
general 2026-10-27
Pharmaron Beijing : CDMO growth and strong orders lifted results, while operating cash flow fell 21.73% - TradingView
Pharmaron Beijing : CDMO growth and strong orders lifted results, while operating cash flow fell 21.73%  TradingView
news Fri, 09 Ja
How HTPD transforms AAV process optimization and scale-up - News-Medical

Frequently Asked Questions About Pharmaron

How many FDA inspections does Pharmaron have on record?
CDMO Signal tracks 5 FDA inspections for Pharmaron, sourced from the FDA inspection database. See the full inspection history above.
Has Pharmaron received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Pharmaron.
Does Pharmaron hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 MHRA GMP certificate for Pharmaron.
What is Pharmaron's CDMO Signal Score?
Pharmaron has a Signal Score of 87/100, based on quality, operations, financial stability, and capacity data.
Evaluating Pharmaron for a manufacturing program?
Use the free AI matchmaker to compare Pharmaron against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid CDMOs → Recombinant Protein CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Ascend Advanced Therapies
Rockville, MD · Alachua, FL · Munich, DE
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish

Compare Pharmaron with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Pharmaron
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.